Science Daily: Pharmacology News
JUNE 23, 2024
Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options. Women experienced greater weight loss and the same symptom benefits compared with men.
Drug Patent Watch
JUNE 23, 2024
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long time needed to obtain regulatory approval for drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drugs.com
JUNE 23, 2024
SUNDAY, June 23, 2024 — When a couple can't get pregnant, the focus is often on the prospective mom, but that needs to change, a Houston urologist says."Both partners need evaluation," said Dr. Larry Lipschultz, a professor of urology at Baylor C.
Drug Patent Watch
JUNE 23, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs. There are three patents protecting this compound. Drug patent litigation for DABIGATRAN ETEXILATE MESYLATE. Nine suppliers are listed for this compound.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
FDA Law Blog: Biosimilars
JUNE 23, 2024
By John A. Gilbert & Karla L. Palmer — For more than 50 years, the Drug Enforcement Administration (DEA) has enforced the central mandate of the Controlled Substances Act (CSA) to maintain a closed chain of distribution for drugs with a potential for abuse and diversion. The CSA and regulations promulgated by DEA are intended to reduce the potential for diversion and abuse and ensure that controlled substances are dispensed and delivered to patients for a legitimate medical purpose.
Drug Patent Watch
JUNE 23, 2024
MOVANTIK (naloxegol oxalate) Valinor Patent: 7,056,500 Expiration: Jun 29, 2024 See More … For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.
Expert insights. Personalized for you.
102 
Let's personalize your content